Rexahn Pharmaceuticals announced that it has enrolled the first patient in its Phase 2b trial of Serdaxin to treat major depressive disorder (MDD). The randomized, double blind, and placebo-controlled study will recruit up to 300 patients and will be conducted at 40 sites in the United States. Serdaxin will be administered as an oral, extended release tablet. Patient enrollment will occur through the first half of 2011, with preliminary data expected in late 2011.
Serdaxin is a dual serotonin and dopamine enhancer being evaluated as a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses.
For more information call (240) 268-5300 or visit www.rexahn.com.